Genotyping Market Size & Share 2023 to 2032

Genotyping Market Size

Genotyping Market size was valued at USD 18.2 billion in 2022 and is estimated to grow at a CAGR of 15.9% between 2023 and 2032. The market is experiencing robust growth, propelled by several key drivers that are shaping the landscape of genetic analysis.

The advent of high-throughput genotyping platforms have significantly enhanced the speed and accuracy of genetic testing, thereby fostering increased adoption across various research and clinical applications. Also, expanding scope of precision medicine and the growing significance of genomics in disease diagnostics and treatment planning are pivotal drivers fuelling the market growth. Additionally, surging interest in understanding genetic variations and their correlation with disease susceptibility, treatment response, and overall health outcomes is another key factor propelling the market forward.
 

Genotyping is the process of determining the genetic makeup of an individual or organism. It involves analysing an organism's DNA to identify variations in specific genes or genetic markers. These genetic variations can include single nucleotide polymorphisms (SNPs), insertions, deletions, or other type of mutations. Further, genotyping is widely used in various fields including genetics research, medicine, and forensics.

COVID-19 Impact

The COVID-19 pandemic had a significant impact on the genotyping market. The demand for genotyping services witnessed both challenges and opportunities during the pandemic. The disruptions in supply chains, workforce limitations, and diversion of resources towards pandemic-related activities hampered the smooth functioning of genotyping laboratories in the early 2020. However, in the latter half, the increased focus on personalized medicine and understanding genetic predispositions to diseases fuelled the demand for genotyping, driving innovation and research in the field, therefore augmenting the market growth.
 

Genotyping Market Trends

• The rising incidence of genetic disorders has emerged as a significant driver for the growth of the market. Genetic disorders, ranging from rare diseases to more common conditions, often have a hereditary component that can be traced through genetic variations.
   
• As advancements in genomics and molecular biology along with rising funding has continued to unfold, there is an increasing awareness regarding the role of genetic factors in the manifestation of various health conditions. This has fueled the demand for genotyping technologies that enable the identification and analysis of genetic variations.
   
• For instance, Genomics Health Futures Mission launched by Australian government, is investing USD 500.1 million in genomic medicine research. Thus, rising investments and funding in genomic research has paved the way for innovative technologies and methodologies in genotyping, thereby supplementing the market growth. However, stringent regulatory requirements may pose a threat to the market expansion.
   

Genotyping Market Analysis

Based on products & services, the market is segmented into reagents & kits, instruments, and software & services. The reagents & kits segment dominated the market in 2022 with a revenue of USD 8.3 billion.
 

• The reagents and kits segment has experienced a surge in demand due to its integral role in facilitating accurate and high-throughput genotyping processes. Laboratories, research institutions, and biotechnology companies increasingly rely on specialized reagents and kits for their genotyping endeavors, thereby fueling the expansion of this market segment.
   
• Additionally, advancements in technology and a surge in genomic research activities have further propelled the demand for reagents and kits.

Learn more about the key segments shaping this market

Download Free PDF

Based on technology, the genotyping market is segmented into PCR, sequencing, microarrays, capillary electrophoresis, Matrix-Assisted Laser Desorption/Ionization-Time of Flight (Maldi-TOF) mass spectroscopy, and other technologies. The PCR segment is further segmented into real-time PCR, digital PCR, and other PCR technologies. The PCR segment dominated the market in 2022 with a business share of 34.6%.
 

• Widespread adoption of PCR can be attributed to its high efficiency in amplifying DNA segments with high precision and speed, making it an indispensable tool for genotyping applications.
   
• Moreover, PCR's cost-effectiveness, compatibility with automation for high-throughput processing, and minimal sample requirements make it an attractive choice for various research and diagnostic applications.
   
• Further, as technological advancements continue to enhance PCR methodologies, the segment is poised to maintain its stronghold in the market.
   

By application, the genotyping market is categorized into diagnostics & personalized medicine, pharmacogenomics, animal genetics, and other applications. The diagnostics & personalized medicine segment is poised for high growth and is anticipated to reach USD 28.7 billion by 2032.
 

• The diagnostic capabilities of genotyping have significantly elevated its applications, allowing healthcare professionals to identify genetic markers associated with various diseases, enabling early detection, prognosis, and personalized treatment plans.
   
• Moreover, the growing demand for precision medicine has driven the integration of genotyping into drug development processes, facilitating the design of targeted therapies based on patients' genetic profiles.
   

By end-use, the genotyping market is segmented into academic & research institute, pharmaceutical & biotechnology companies, diagnostic centers, and other end-users. Wide application of genotyping data in research is anticipated to propel the growth of academic & research organizations.
 

• Academic & research organizations have embraced genotyping as a powerful tool to unravel the complexities of diseases, identify biomarkers, and personalize therapeutic strategies.
   
• With their substantial budgets and focus on interdisciplinary research, academic institutes and research centers continue to be key drivers of innovation in the genotyping industry, thereby aiding in high segment expansion.

North America accounted for the largest business share of 41.4% of the genotyping market in 2022.
 

• The market in North America has experienced a remarkable surge in growth, marked by technological advancements, increasing research & development activities, and a growing demand for personalized medicine.
   
• The region's robust healthcare infrastructure, coupled with significant investments in genomics research, has propelled the adoption of genotyping technologies across various sectors.
   
• Additionally, the rising prevalence of chronic diseases and the increasing awareness of the potential benefits of genotyping for disease prevention and treatment have contributed to the escalating demand for genotyping services and products in North America, thereby driving the regional market trends.
   

Genotyping Market Share

The market is characterized by diverse players competing in the industry. Illumina Inc., Thermo Fisher Scientific Inc., QIAGEN N.V., and Danaher Corporation account for significant market share. These prominent players thrive through a combination of strategic initiatives, investing in research and development, geographical expansion, strategic approaches, product diversification, and regulatory compliance.
 

The foremost market players operating in the genotyping industry is as mentioned below:

• Illumina Inc.
• Thermo Fisher Scientific Inc.
• QIAGEN N.V
• F. Hoffmann-La Roche Ltd.
• Standard BioTools Inc.
• Danaher Corporation
• Agilent Technologies, Inc.
• Eurofins Scientific
• GE Healthcare Technologies Inc.
• Bio-Rad Laboratories Inc.
   

Genotyping Industry News:

• In September 2023, Bio-Rad Laboratories, Inc. launched its PTC Tempo 48/48 and PTC Tempo 384 Thermal Cycler for sequencing, cloning, and genotyping. These new products offer superior thermal performance and enhanced usability. This helped the company to cater to a larger customer base.
   
• In August 2022, Thermo Fisher Scientific, launched its Applied Biosystems HIV-1 Genotyping Kit, which examines positive samples of human immunodeficiency virus (HIV) to identify genetic variants that resist common antiretroviral therapeutics. This enhanced the company’s existing genotyping product offerings.
   

The genotyping market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

By Product & Services, 2018 – 2032 (USD Million)

• Reagents & kits
• Instruments
• Software & services

By Technology, 2018 – 2032 (USD Million)

• PCR
  • Real-time PCR
  • Digital PCR
  • Other PCR technologies 
• Sequencing
  • Next generation sequencing
  • Sanger sequencing
• Microarrays
  • DNA microarrays
  • Peptide microarrays
  • Other microarray technologies
• Capillary electrophoresis
  • Amplified fragment length polymorphism
  • Restriction fragment length polymorphism
  • Single-strand conformation polymorphism
• Matrix-Assisted Laser Desorption/Ionization-Time of Flight (Maldi-TOF) mass spectroscopy
• Other technologies

By Application, 2018 – 2032 (USD Million)

• Diagnostics and personalized medicine
• Pharmacogenomics
• Animal genetics
• Other applications

By End-use, 2018 – 2032 (USD Million)

• Academic and research institute
• Pharmaceutical and biotechnology companies
• Diagnostic centers
• Other end-users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of Middle East & Africa